Stem Cell Donation: Process, Eligibility, and What to Expect

Stem cell donation is a medical procedure in which healthy blood-forming cells are collected from a donor and transferred to a patient whose own bone marrow has failed or been destroyed by disease. This article explains the two main collection methods, the eligibility screening process, what happens before and after donation, and the known risks and recovery patterns. It is written for laboratory students, technicians, researchers, and diagnostic professionals who may encounter donor workup samples, HLA typing requests, or cell product quality assessments, and who need a clear picture of the clinical pathway that surrounds those laboratory tasks.

At a Glance

The table below summarizes the key features of the two standard donation methods and the registry enrollment pathway.

The choice between PBSC donation and bone marrow harvest depends on the recipient's disease, the transplant center's protocol, and donor characteristics. Both methods are considered safe for healthy donors when selection and evaluation are performed carefully. The safety record for bone marrow donation has been documented over more than 30 years of clinical use, with the main risks related to anesthesia and postoperative pain instead of to the loss of stem cells themselves. A review of bone marrow donation safety reported that among 27,770 first transplant procedures from bone marrow donors in a European registry analysis, one fatal event and 12 serious adverse events were observed, with cardiac events being the most frequent serious complications. The same review noted that the incidence of adverse events was significantly lower for bone marrow donors compared with peripheral blood stem cell donors, which underscores the need for careful donor selection and evaluation in both pathways.

Understanding Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation replaces a patient's diseased or destroyed blood-forming system with healthy stem cells from a donor. The procedure is a treatment of choice for a variety of malignant and non-malignant disorders, and it places considerable physical and emotional demands on both recipients and donors. The identification of a suitable donor is a prerequisite for the transplant, and the choice of donor affects the entire transplantation process, from scheduling to post-transplant outcomes.

Allogeneic transplantation uses stem cells from another person instead of from the patient themselves. The donor may be a matched sibling, a related family member, or an unrelated volunteer found through a registry. The goal is to replace the patient's hematopoiesis, meaning the production of blood cells, with that of the donor. This replacement provides the patient with a new immune system that can fight residual disease and restore normal blood cell production.

The stem cells used in transplantation are hematopoietic stem cells, which are the self-renewing cells in bone marrow that give rise to all blood cell types. These cells circulate in small numbers in the peripheral blood, and their numbers can be increased with growth factor stimulation. They can also be collected directly from bone marrow. Both collection methods yield a product that can be infused into the recipient through a central venous catheter, similar to a blood transfusion.

Donor Registries and the Matching Process

Unrelated donor transplantation depends on registries that maintain HLA typing information for large numbers of volunteer donors. When a patient needs a transplant, the transplant center searches registries for donors whose HLA type matches the patient's. HLA, or human leukocyte antigen, is the protein system the immune system uses to distinguish self from non-self. A close HLA match reduces the risk of graft rejection and graft-versus-host disease.

Registry enrollment begins with a simple blood sample or buccal swab for HLA typing. No medical procedure is required at this stage, and enrollment does not commit a person to donate. The donor remains on the registry until a match is identified, at which point the donor undergoes a thorough medical evaluation to confirm fitness for donation.

The demand for donors is ongoing because HLA types are highly diverse, and patients from minority ethnic backgrounds often have difficulty finding matches. Studies of medical students and college students have examined knowledge and attitudes toward stem cell donation, with findings suggesting that educational level and prior training influence willingness to donate. One cross-sectional study of medical students found that only 2.1 percent had donated stem cells, while 38.9 percent intended to donate, and knowledge scores averaged 54.3 percent of the maximum possible. Reluctance to donate was most often attributed to anticipated pain and concerns about adverse effects. These findings indicate that accurate information about the donation process can address common misconceptions and support donor recruitment.

Eligibility Criteria for Stem Cell Donation

Eligibility for stem cell donation is determined by medical history, physical examination, and laboratory testing. The goal is to protect both the donor and the recipient. Donors must be healthy enough to undergo the collection procedure and must be free of conditions that could be transmitted to the recipient or that could compromise the quality of the stem cell product.

General Health Requirements

Donors are typically required to be between 18 and 60 years of age, although specific age limits vary by registry and transplant center. Donors must be in generally good health, with no uncontrolled chronic conditions such as heart disease, diabetes, or hypertension. Body weight is considered because it affects the volume of blood that can be processed during apheresis and the number of stem cells that can be collected.

Medical History Screening

The medical history review covers previous surgeries, hospitalizations, and chronic illnesses. Donors with active infections, autoimmune diseases, or a history of certain cancers are typically excluded. The screening also assesses risk factors for blood-borne infections, including hepatitis, HIV, and other transmissible diseases. The evaluation is designed to identify any condition that could increase the donor's risk of complications or that could be passed to the recipient through the stem cell product.

Laboratory Testing

Laboratory testing for potential donors includes complete blood count, blood chemistry panel, and screening for infectious diseases. HLA typing is performed to confirm the match with the recipient. Additional testing may include blood type and antibody screening, as ABO blood group compatibility is a critical factor in stem cell transplantation. In ABO-incompatible transplantation, recipient antibodies against donor A or B antigens can bind to donor red cells or endothelial cells and trigger complement activation, potentially leading to antibody-mediated rejection and early graft loss. Measurement of these antibodies by titration is essential for assessing transplant suitability, although the lack of international standardization in titration methods can lead to inter-laboratory variability and influence transplant eligibility decisions.

Pregnancy and Breastfeeding

Pregnant women are generally excluded from donation because of the risks of the procedure and the medications used. Breastfeeding women may be deferred until after weaning, depending on registry policy and the urgency of the transplant.

Peripheral Blood Stem Cell Donation

Peripheral blood stem cell donation is the most common collection method for adult donors. It involves stimulating the bone marrow to release stem cells into the bloodstream and then collecting those cells through apheresis.

Growth Factor Stimulation

For several days before collection, the donor receives injections of filgrastim, a granulocyte colony-stimulating factor that increases the number of hematopoietic stem cells in the peripheral blood. The injections are typically given once or twice daily for 4 to 5 days. Common side effects include bone pain, headache, fatigue, and flu-like symptoms. These effects resolve after the injections stop and the collection is complete.

Apheresis Collection

Apheresis is a process in which blood is drawn from one arm, passed through a machine that separates out the stem cells, and the remaining blood components are returned to the donor through the other arm. The procedure takes 4 to 6 hours and may need to be repeated on a second day if the stem cell yield is insufficient. The target is to collect a sufficient number of CD34-positive cells, which are the cells that express the CD34 surface marker characteristic of hematopoietic stem and progenitor cells.

Recovery After PBSC Donation

Most donors return to normal activities within a few days. The bone pain and fatigue from the growth factor injections typically resolve within a week. Serious complications are rare but can include splenic rupture, which is a rare but potentially life-threatening event associated with filgrastim administration. Donors are advised to report any severe abdominal pain or other unusual symptoms promptly.

Bone Marrow Harvest

Bone marrow harvest is a surgical procedure performed under general or regional anesthesia. The donor is admitted to the hospital, and the procedure takes place in an operating room.

Surgical Procedure

The surgeon inserts a needle through the skin and into the posterior iliac crest, which is the back part of the pelvic bone. Multiple punctures are made to aspirate bone marrow from the spongy interior of the bone. The volume collected depends on the recipient's weight and the target cell dose, typically ranging from 500 to 1,500 milliliters. The marrow is then filtered and processed before being transported to the recipient's transplant center.

Hospital Stay and Recovery

Bone marrow donation requires a hospital admission of 1 to 3 days, and donors typically need 7 to 10 days off work. The main risks are related to anesthesia. Pain in the aspiration area and asthenia, which is a feeling of weakness or lack of energy, are the most frequent side effects. The safety record for bone marrow donation is well established, with the procedure having been performed for more than 30 years. Serious adverse events are rare, and the most frequent serious complications are cardiac in nature.

Comparison with PBSC Donation

The choice between bone marrow harvest and PBSC donation involves tradeoffs. Bone marrow harvest requires anesthesia and a hospital stay, while PBSC donation requires growth factor injections and apheresis. The recovery time is generally longer for bone marrow harvest, but the incidence of adverse events has been reported to be lower for bone marrow donors compared with PBSC donors. The transplant center makes the decision based on the recipient's disease, the urgency of the transplant, and the donor's anatomy and health status.

The Donation Timeline

The donation process follows a structured timeline that begins with registry enrollment and ends with post-donation follow-up. Understanding this timeline helps donors and laboratory professionals know what to expect at each stage.

Step 1: Registry Enrollment and HLA Typing

The first step is enrollment in a donor registry, which involves providing a blood sample or buccal swab for HLA typing. The donor's HLA type is entered into the registry database, and the donor remains available for matching until the age limit or voluntary withdrawal.

Step 2: Confirmatory Typing and Medical Evaluation

When a potential match is identified, the donor undergoes confirmatory HLA typing to verify the match. This is followed by a comprehensive medical evaluation, including history, physical examination, and laboratory testing. The evaluation confirms that the donor is healthy enough to donate and that the stem cell product will be safe for the recipient.

Step 3: Donor Education and Informed Consent

The donor receives detailed information about the collection procedure, the risks, and the expected recovery. The informed consent process ensures that the donor understands what will happen and voluntarily agrees to proceed. Donors are encouraged to ask questions and to discuss the decision with family members and healthcare providers.

Step 4: Collection Procedure

The collection procedure is scheduled at a transplant center or collection facility. For PBSC donation, the donor receives growth factor injections for several days before apheresis. For bone marrow harvest, the donor is admitted to the hospital and undergoes the surgical procedure under anesthesia.

Step 5: Post-Donation Follow-Up

After donation, the donor is monitored for complications and recovery. Follow-up contact occurs at intervals after the procedure to assess recovery and to document any adverse events. This monitoring is part of the donor safety protocol and contributes to the ongoing evaluation of donation safety.

Donor Safety and Adverse Events

Donor safety is the highest priority in the donation process. Both the Joint Accreditation Committee and the European Committee have emphasized the importance of monitoring adverse events and adverse reactions in stem cell donation. The ethical foundation of donation and its central role in transplantation require that the greatest attention be given to the donor and to the donation process through a serious monitoring protocol.

Known Risks of PBSC Donation

The most common side effects of PBSC donation are related to the growth factor injections. Bone pain, headache, and fatigue are reported by most donors and typically resolve within a week of the last injection. More serious complications are rare but can include splenic rupture, which requires emergency medical attention. Donors are instructed to seek immediate care if they experience severe left upper abdominal pain, shoulder pain, or other signs of splenic injury.

Known Risks of Bone Marrow Harvest

The main risks of bone marrow harvest are related to anesthesia. Donors may experience nausea, sore throat from the breathing tube, and dizziness after the procedure. Pain at the aspiration sites is common and may persist for several days. The recovery period includes 1 to 3 days in the hospital and 7 to 10 days off work. Serious adverse events are rare, with cardiac events being the most frequently reported serious complications in registry analyses.

Long-Term Effects

Research on the long-term effects of stem cell donation is ongoing. The available evidence indicates that donation is safe for healthy donors, but the full picture of long-term effects requires continued follow-up. Donors are encouraged to report any health changes to the registry or transplant center, and registries maintain systems for tracking adverse events over time.

Laboratory Considerations in Stem Cell Donation

Laboratory professionals play a critical role in the stem cell donation pathway. The workup of potential donors involves multiple laboratory tests, and the quality of the collected product must be verified before it is released for transplantation.

HLA Typing and Crossmatching

HLA typing is performed using molecular methods that identify the specific alleles at the HLA loci. High-resolution typing provides the detailed information needed to select the best-matched donor. Crossmatching may be performed to detect donor-specific antibodies that could cause graft rejection.

Infectious Disease Screening

Donors are screened for infectious diseases including HIV, hepatitis B and C, and other transmissible agents. The screening is performed on blood samples collected at the time of the medical evaluation and again shortly before the collection procedure. The results must be negative for the donor to proceed.

ABO Blood Group Testing

ABO blood group compatibility is a critical factor in stem cell transplantation. The donor and recipient ABO types are determined, and if they are incompatible, the transplant center plans for red cell depletion of the marrow product or plasma depletion of the apheresis product. Antibody titration may be performed to assess the level of isohemagglutinins, which are antibodies against A or B blood group antigens. The lack of international standardization in antibody titration methods is a recognized limitation, as variations in techniques, reagents, incubation conditions, and endpoint definitions can lead to significant inter-laboratory variability.

Cell Product Quality Assessment

The collected stem cell product is assessed for cell count, viability, and CD34-positive cell content. The CD34-positive cell dose is the primary predictor of engraftment success. The product is also tested for sterility and may undergo additional processing such as red cell depletion or cryopreservation before transplantation.

Documentation and Traceability

Accurate documentation is essential throughout the donation process. Laboratory records must include donor identification, test results, product processing details, and quality control data. Traceability ensures that the product can be tracked from collection to infusion and that any adverse events can be investigated. The principles of laboratory quality management, as described in the World Health Organization's Laboratory Quality Management System Handbook, apply to the testing and documentation practices in the stem cell donation pathway.

Quality Control and Biosafety in the Laboratory

Laboratory testing for stem cell donation must be performed under controlled conditions to ensure accurate and reliable results. The World Health Organization's Laboratory Quality Management System Handbook provides guidance on the management of laboratory processes, including document control, equipment maintenance, and personnel training. The Laboratory Biosafety Manual from the World Health Organization addresses the safe handling of biological materials, including blood samples and cell products.

Pre-Analytical Variables

The quality of laboratory results depends on proper specimen collection, handling, and transport. Blood samples for HLA typing and infectious disease screening must be collected in the correct tubes, labeled accurately, and transported to the laboratory under appropriate conditions. Hemolyzed or clotted samples may produce unreliable results and require recollection.

Analytical Quality Control

Laboratories performing testing for stem cell donation must participate in external quality assessment programs and use internal quality control materials to monitor assay performance. The U.S. Food and Drug Administration's Bioanalytical Method Validation Guidance describes the expectations for method validation, including accuracy, precision, selectivity, and stability. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides additional information on assay development and validation.

Post-Analytical Considerations

Results must be reviewed and interpreted by qualified personnel before release. Critical results, such as a positive infectious disease screen or an unexpected HLA type, must be communicated promptly to the transplant center. The laboratory must maintain records of all testing and result reports in accordance with regulatory requirements.

Biosafety Practices

Laboratory personnel handling blood samples and stem cell products must follow standard precautions, including the use of personal protective equipment and proper hand hygiene. Procedures that may generate aerosols must be performed in a biological safety cabinet. The Laboratory Biosafety Manual from the World Health Organization provides detailed guidance on risk assessment and the selection of appropriate containment measures.

Common Failure Patterns and Troubleshooting

Several problems can arise during the stem cell donation process, and laboratory professionals should be prepared to recognize and address them.

Insufficient Stem Cell Yield

The most common problem in PBSC donation is an insufficient CD34-positive cell yield. This can occur if the donor does not respond adequately to growth factor stimulation or if the apheresis procedure is not optimized. The collection may be repeated on a second day, or the transplant center may adjust the target cell dose. Donors who fail to mobilize sufficient cells may be switched to bone marrow harvest.

Clotted or Hemolyzed Samples

Blood samples for laboratory testing can clot or hemolyze if not handled properly. This can delay the donor workup and require recollection. Laboratories should have procedures in place for specimen rejection and recollection to minimize delays.

ABO Incompatibility Issues

ABO-incompatible transplantation requires careful planning to prevent antibody-mediated rejection. The laboratory must accurately determine the ABO type of both donor and recipient and perform antibody titration when indicated. Variability in titration methods can lead to inconsistent results, and laboratories should use standardized protocols where available.

Contamination of the Cell Product

The stem cell product can become contaminated with bacteria or fungi during collection or processing. Sterility testing is performed to detect contamination, and positive results require investigation and may lead to product discard. The collection and processing procedures must be performed under sterile conditions to minimize the risk of contamination.

Documentation Errors

Errors in documentation can compromise traceability and patient safety. Laboratories must have systems in place to verify donor identification, match test results to the correct donor, and ensure that all required records are complete and accurate. Regular audits can identify and correct documentation problems.

Limitations and Uncertainties in Stem Cell Donation

The stem cell donation process has limitations that should be acknowledged. The safety data for donation are derived from registry analyses and clinical studies, but the long-term effects on donors are not fully characterized. The incidence of serious adverse events is low, but rare complications can occur, and donors should be informed of these risks during the consent process.

The success of transplantation depends on many factors beyond the donation process, including the recipient's disease status, the conditioning regimen, and the degree of HLA match. Even with a well-matched donor, transplantation carries significant risks of morbidity and mortality. The donation process is only one component of a complex treatment pathway.

Research on stem cell biology continues to advance understanding of hematopoietic stem cell function and aging. Studies using single-cell analysis have revealed the diversity of stem cell clones and their behavior during aging, with implications for understanding clonal hematopoiesis and the effects of transplantation. The metabolism of stem cells is also an area of active investigation, with evidence that stem cells primarily generate energy through glycolysis and that metabolic shifts occur during differentiation. These findings may inform future approaches to improving stem cell collection and transplantation outcomes.

Professional Escalation Criteria

Laboratory professionals should escalate concerns to the transplant center or medical director in specific situations. These include unexpected or discrepant HLA typing results, positive infectious disease screens, abnormal blood counts or chemistry results, and evidence of sample contamination or mislabeling. Any result that could affect donor safety or product quality should be communicated promptly.

Donors who experience severe or persistent symptoms after donation should be referred for medical evaluation. Symptoms that require urgent attention include severe abdominal pain, chest pain, difficulty breathing, fever, and signs of infection at the collection site. The transplant center or registry should be notified of any adverse events so that they can be documented and investigated.

Frequently Asked Questions

How long does the stem cell donation process take from start to finish?

The timeline varies by collection method. For peripheral blood stem cell donation, the growth factor injections take 4 to 5 days, and the apheresis collection takes 4 to 6 hours, sometimes repeated on a second day. For bone marrow harvest, the procedure itself takes 1 to 2 hours under anesthesia, followed by a hospital stay of 1 to 3 days. The full process from confirmatory typing to collection typically takes several weeks, depending on the urgency of the transplant and the scheduling of the donor workup.

Is stem cell donation painful?

Peripheral blood stem cell donation involves injections that can cause bone pain, headache, and fatigue, which usually resolve within a week. The apheresis procedure itself is not painful, though donors may experience tingling from the anticoagulant used during the procedure. Bone marrow harvest is performed under anesthesia, so the donor does not feel pain during the procedure. After the anesthesia wears off, donors typically experience soreness at the aspiration sites for several days.

Can anyone register as a stem cell donor?

Most registries accept volunteers between 18 and 60 years of age who are in generally good health. People with certain medical conditions, including active infections, autoimmune diseases, and a history of cancer, may not be eligible. The eligibility criteria are designed to protect both the donor and the recipient, and the final determination is made during the medical evaluation after a potential match is identified.

What is the difference between peripheral blood stem cell donation and bone marrow harvest?

Peripheral blood stem cell donation uses growth factor injections to move stem cells from the bone marrow into the bloodstream, where they are collected by apheresis. Bone marrow harvest is a surgical procedure in which marrow is aspirated directly from the pelvic bone under anesthesia. The choice between the two methods depends on the recipient's disease, the transplant center's protocol, and donor characteristics.

Are there any long-term health risks from donating stem cells?

The available evidence indicates that stem cell donation is safe for healthy donors, with serious adverse events being rare. The long-term effects are not fully characterized, and registries maintain follow-up systems to track donor health over time. Donors are encouraged to report any health changes to the registry or transplant center.

Can I donate stem cells to a family member?

Yes, related donors are a common source of stem cells for transplantation. Siblings are the most likely family members to be HLA-matched, but parents, children, and other relatives may also be considered. The donation process for a related donor is the same as for an unrelated donor, with the same medical evaluation and collection procedures.

What happens to my stem cells after I donate?

The collected stem cells are processed and tested in the laboratory before being transported to the recipient's transplant center. The product may undergo red cell depletion, plasma depletion, or cryopreservation depending on the transplant protocol. The cells are then infused into the recipient through a central venous catheter, and the recipient is monitored for engraftment and complications.

How are stem cell donors matched to recipients?

Donors and recipients are matched based on HLA type, which is determined by molecular testing. A close HLA match reduces the risk of graft rejection and graft-versus-host disease. The matching process also considers ABO blood group compatibility and the presence of donor-specific antibodies. The transplant center searches registries for donors whose HLA type matches the recipient's and selects the best-matched donor available.

Related Diagnostic Guides

• How to Prepare and Pour Agar Plates for Microbiology: A Step-by-Step Guide
• How to Prepare Competent Cells for Bacterial Transformation: A Step-by-Step Protocol
• How to Prepare a Bacterial Smear for Gram Staining: Step-by-Step Protocol
• Process Controls in Microbiology: Internal Amplification Controls and Their Role
• Process Controls in PCR: Internal Amplification Controls and Their Role in Validation

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Allogeneic Stem Cell Donation.. JAMA, 2025.
• A single-cell transcriptome atlas of the adult human retina.. The EMBO journal, 2019.
• Donor Selection.. 2018.
• Clonal tracing with somatic epimutations reveals dynamics of blood ageing.. Nature, 2025.
• Stem Cell Metabolism: Powering Cell-Based Therapeutics.. Cells, 2020.
• The modeling of human implantation and early placentation: achievements and perspectives.. Human reproduction update, 2025.
• Human embryonic stem cell-derived immunity-and-matrix-regulatory cells promote endometrial repair and fertility restoration in IUA rats.. Stem cell research & therapy, 2025.
• Safety of bone marrow stem cell donation: a review.. Transplantation proceedings, 2010.
• Hematopoietic Cell Transplantation for Sickle Cell Disease. 2026.
• A perspective on ABO incompatible transplantation.. 2026.
• Are tomorrow's doctors ready to donate? Insights into medical students' knowledge and attitudes on stem cell donation: a cross-sectional study.. 2026.
• Clinical and Molecular Characterization of &lt,i&gt,TCIRG1&lt,/i&gt,-Related Autosomal Recessive Osteopetrosis with Current Therapeutic Approaches.. 2026.
• HLA incompatibility mitigation strategies in off-the-shelf cancer immunotherapies: clinical implications and a practical framework for strategy selection and combination.. 2026.
• Effect of knowledge and attitude on intention for hematopoietic stem cell donation among college students in Korea. International Journal of Applied Engineering Research, 2014.
• Knowledge and Attitudes of Faculty of Health Sciences Students towards Hematopoietic Stem Cell Donation. International Journal of Hematology Oncology and Stem Cell Research, 2024.
• Development and Investigation of a Free and Informed Choice Process for Embryo Donation to Stem Cell Research in Canada. Journal of Obstetrics and Gynaecology Canada, 2006.
• The core of sibling stem cell donation-A grounded theory study. Open Nursing Journal, 2017.
• Being a haematopoietic stem cell donor for a sick sibling: Adult donors' experiences prior to donation. European Journal of Oncology Nursing, 2015.
• The influence of the donor-recipient relationship on related donor reactions to stem cell donation. Bone Marrow Transplantation, 2014.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.